Mesothelioma Diagnostic Technology

Connecting to wikimesothelioma.com... Logging in as MesotheliomaSupport@Claude... Successfully logged in!

--- Page Content ---

Mesothelioma Diagnostic Technology (2025–2026)
Current staging	IASLC TNM 9th ed. (Jan 2025) — pleural thickness sum (Psum)
Tissue gold standard	BAP1 IHC + MTAP IHC (100% specificity for malignancy)
FDA-approved serum biomarker	MESOMARK (SMRP) — monitoring only, not diagnosis
Liquid biopsy (emerging)	cfMeDIP-seq methylation — 91% accuracy (2025 ASCO)
AI pathology	SpindleMesoNET AUC 0.989; MesoNet validated; no FDA-cleared mesothelioma-specific tool
Germline testing	BAP1 germline testing — ASCO 2025 Strong Recommendation for all patients
Histology classification	WHO 5th ed. (2021) — epithelioid, biphasic, sarcomatoid; WDPMT reclassified non-malignant
Verified	2026-05-13

Executive Summary

The 2023–2026 period delivered the largest set of mesothelioma diagnostic advances in two decades. Four shifts now define current practice:

The IASLC TNM 9th edition, published January 2025, replaced anatomically defined T1–T4 invasion descriptors with pleural thickness sum (Psum) measured at three axial CT levels — a continuous, reproducible variable that stratifies median overall survival from 49.8 months at Psum ≤12 mm to 21.1 months at Psum >31 mm.

In pathology, MTAP immunohistochemistry has emerged as a practical surrogate for CDKN2A homozygous deletion, supplementing BAP1 IHC as the two-marker rule-in panel for malignant mesothelial proliferation. Both can now be applied to cytology effusion cell blocks with 100% specificity, enabling diagnosis from pleural fluid in expert centers.

The WHO 5th Edition Classification of Thoracic Tumours (2021) reclassified well-differentiated papillary mesothelial tumor (WDPMT) as a non-malignant entity and formally recognized mesothelioma in situ as a diagnostic category requiring BAP1 loss and/or CDKN2A deletion.

In liquid biopsy, the cfMeDIP-seq epigenetic platform achieved 91% accuracy with histotype discrimination in the largest prospective pleural mesothelioma cohort to date (2025 ASCO Annual Meeting). The IMPRESS tissue methylation assay demonstrated 100% specificity for distinguishing pleural mesothelioma from pleural metastases. Germline BAP1 testing is now an ASCO 2025 Strong Recommendation for all patients. No new serum biomarker has received FDA approval since MESOMARK in 2007.

At a Glance

• Staging: IASLC TNM 9th edition (January 2025) uses pleural thickness sum on CT, replacing 8th edition anatomical T-categories.
• Tissue diagnosis: BAP1 IHC loss + MTAP IHC loss = 100% specificity for malignant mesothelial proliferation.
• Imaging first-line: Multi-detector CT (sensitivity 68%, specificity 78%); MRI superior for chest-wall and diaphragm invasion; PET-CT sensitivity ~95% for malignant pleural disease but limited (~30% nodal upstaging at surgery).
• Liquid biopsy: MESOMARK (SMRP) is the only FDA-approved serum biomarker (monitoring, not diagnosis); cfMeDIP-seq, IMPRESS methylation, fibulin-3, and ctDNA are investigational.
• AI pathology: SpindleMesoNET (AUC 0.989) equals expert pathologists for sarcomatoid vs. benign spindle classification; MesoNet (Nature Medicine 2019) predicts outcome from whole-slide images. No mesothelioma-specific AI tool has FDA clearance.
• Germline testing: BAP1 testing recommended for all patients (ASCO 2025); ~20% of mesotheliomas have hereditary underpinning.
• Differential diagnosis: BAP1 + MTAP (or CDKN2A FISH) is the core panel to distinguish malignant mesothelioma from reactive mesothelial proliferation; solitary fibrous tumor identified by STAT6 / NAB2-STAT6 fusion.
• Subtype: Epithelioid (~55–60%), biphasic (~20–25%), sarcomatoid (~10–20%); sarcomatoid carries the worst prognosis and per ASCO 2025 contraindicates maximal surgical cytoreduction.

Key Facts

Diagnostic Tool	FDA Status	Best Performance	Primary Use	Guideline Status (2026)
MESOMARK (SMRP, serum)	Approved 2007	Sensitivity 47–68% / specificity 86–96%	Monitoring epithelioid or biphasic MPM	ASCO 2025: not recommended for diagnosis
Fibulin-3 (plasma)	Not approved	100% specificity / 39% sensitivity (Jiang 2025 cohort)	Investigational	Not recommended (ASCO 2025)
cfMeDIP-seq (plasma methylation)	Not approved	91% accuracy, histotype discrimination (n=55, 2025 ASCO)	Investigational	⚠️ Emerging — not in NCCN/ESMO/ASCO 2025
IMPRESS (tissue methylation)	Not approved	Specificity 100% for PM vs. pleural metastases	Investigational	⚠️ Emerging
BAP1 IHC (tissue or cytology)	Clinical use	Specificity 100%, sensitivity 56%	Rule-in malignancy	IMIG / WHO endorsed
MTAP IHC (CDKN2A surrogate)	Clinical use	~95% concordance with CDKN2A FISH	Rule-in malignancy	⚠️ Emerging in IMIG 2024 practice updates
CDKN2A FISH	Clinical use	Specificity 100%; sensitivity 60–80% (sarcomatoid), 15–30% (epithelioid)	Rule-in malignancy	IMIG / WHO endorsed
MesoNet AI (WSI)	Research only	Improves OS prediction beyond pathologist annotation	Outcome prediction	Research
SpindleMesoNET (CNN)	Research only	AUC 0.989; accuracy 92.5% (vs. 91.7% expert average)	Sarcomatoid vs. benign spindle	Research
PET-CT (¹⁸F-FDG)	Standard of care	Sensitivity ~95% for malignant pleural disease; ~30% nodal upstaging at surgery	Staging	NCCN / ASCO endorsed
TNM 9th edition (Psum)	In use Jan 2025	Median OS 49.8 mo (T1) → 21.1 mo (T3)	Pleural mesothelioma staging	IASLC / UICC endorsed

What Are the Latest Imaging Advances for Mesothelioma in 2025–2026?

Multi-detector CT (First-Line)

CT scanning has a sensitivity of approximately 68% and specificity of approximately 78% for detecting pleural malignancy, and cannot reliably differentiate diffuse pleural mesothelioma from metastatic pleural disease. Multi-detector CT (MDCT) remains the first-line modality for suspected pleural mesothelioma. Classic findings include unilateral pleural effusion, nodular or circumferential pleural thickening greater than 1 cm, a pleural rind encasing the lung, and involvement of the mediastinal or diaphragmatic pleura. CT cannot reliably assess chest-wall invasion (the T3/T4 boundary) or transmural pericardial involvement — limitations that drive the use of MRI for surgical candidates.

18F-FDG PET-CT

PET-CT distinguishes malignant from benign pleural lesions with a sensitivity of approximately 95% and specificity of approximately 82% for malignant pleural disease. PET-CT sensitivity for mediastinal lymph node staging is limited: pathological upstaging of the N-category occurs in approximately 30% of cases at surgery, making PET-CT insufficient as a standalone staging tool for surgical candidates. False positives include tuberculous pleurisy, prior talc pleurodesis (with SUV reaching 3–5 at pleurodesis sites for months), empyema, and asbestos-related benign pleuritis.

MRI for Chest-Wall and Diaphragm Assessment

MRI is superior to CT for evaluating chest-wall invasion, diaphragmatic muscle invasion, and pericardial involvement — all critical T3/T4 distinctions in the new staging system. Diffusion-weighted MRI (DWI) identifies areas of restricted diffusion corresponding to viable tumor, and MRI is the standard modality of choice when surgical candidacy depends on resolution of soft-tissue invasion that CT cannot reliably assess. Hyperpolarized MRI using ¹³C-pyruvate has shown proof-of-concept in early-phase UK lung and pleural malignancy trials but no mesothelioma-specific hyperpolarized MRI diagnostic data have been published in peer-reviewed literature as of May 2026 — it remains investigational.

TNM 9th Edition: Pleural Thickness Measurement (Major 2025 Change)

The IASLC 9th edition TNM for pleural mesothelioma, published January 2025, introduced pleural thickness sum (Psum) measured at three axial CT levels — apex, hilum, and base — as the primary T-descriptor, replacing the 8th edition's anatomically defined T1–T4 invasion-based categories. The change was driven by data showing the 8th edition T-categories had poor inter-observer reproducibility and that pleural thickness was a more continuous, objectively measurable prognostic variable. The new descriptors stratify median overall survival sharply:

• T1 (Psum ≤12 mm) — median overall survival 49.8 months
• T2 (Psum 12–30 mm) — median overall survival 27.5 months
• T3 (Psum >31 mm) — median overall survival 21.1 months

The N-descriptor was largely retained (ipsilateral intrathoracic nodes = N1; contralateral or supraclavicular = N2). The 8th edition stage groupings remain in widespread use during the 2025–2026 transition.

Which Liquid Biopsy Tools Are Available for Mesothelioma?

MESOMARK (Soluble Mesothelin-Related Peptides, SMRP)

The MESOMARK assay (Fujirebio Diagnostics) is the only FDA-approved serum biomarker for mesothelioma as of May 2026. FDA approval was granted January 24, 2007 for monitoring disease response or progression in epithelioid or biphasic pleural mesothelioma — not for primary diagnosis or screening.

Diagnostic performance across major studies has been heterogeneous:

• Robinson et al., The Lancet, 2003 — sensitivity 84%, specificity 95% (original landmark study)
• Hollevoet et al. individual patient data meta-analysis — pooled sensitivity 47% (range 19–68%) at specificity 96% (range 88–100%), most rigorous analysis to date
• At a predefined 99% specificity (screening context), sensitivity drops to 23%

A 25% change in serum mesothelin from baseline was identified as the optimal threshold for detecting disease progression (sensitivity 48.7%, specificity 75.7%) — the basis for MESOMARK's monitoring indication. The SOMAscan SOMAmer-based proteomics platform differentiated pleural mesothelioma from asbestos-exposed controls in the DIAPHRAGM study with sensitivity 75% and specificity 88.2%, but was not useful for distinguishing mesothelioma from non-mesothelioma patients presenting with suspected pleural malignancy.

Fibulin-3 (EFEMP1) — Not FDA Approved

Fibulin-3 was initially reported with extraordinary diagnostic performance in the 2012 Pass et al. study (AUC 0.99, sensitivity 95%, specificity 95% for mesothelioma vs. asbestos-exposed controls). Subsequent validation has not replicated the original results. In the multicenter DIAPHRAGM study (638 patients with suspected pleural malignancy, 112 asbestos-exposed controls), fibulin-3 demonstrated only 7.4%–11.9% sensitivity at 95% specificity — significantly inferior to mesothelin. A 2025 prospective study by Jiang et al. (Radiology and Oncology, 90 thoracoscopic-biopsy patients) found plasma fibulin-3 at a 12.31 ng/mL cutoff offered 100% specificity but only 39.39% sensitivity for distinguishing mesothelioma from asbestos-related benign pleural disease (AUC 0.78). A composite panel of serum fibulin-3 + mesothelin + HMGB1 achieved sensitivity 96% and specificity 93% in one retrospective study — substantially outperforming any single marker, but requires prospective validation.

HMGB1 (High Mobility Group Box 1) — Investigational

HMGB1, particularly its hyperacetylated isoform, has shown promise as a serum biomarker for detecting asbestos exposure and early mesothelioma via the RAGE receptor/Beclin-1 autophagy pathway. HMGB1 is not FDA-approved for any diagnostic indication in mesothelioma as of May 2026. Large-scale prospective validation is pending.

ctDNA and Methylation-Based Liquid Biopsy (Emerging)

Circulating tumor DNA (ctDNA) profiling faces unique obstacles in mesothelioma due to the absence of recurrent gain-of-function driver mutations — the disease is driven predominantly by loss of tumor suppressor genes (BAP1, NF2, CDKN2A), making conventional mutation-based ctDNA panels poorly suited for detection. The most promising approach is epigenetic methylation-based ctDNA analysis. A 2025 ASCO Annual Meeting abstract reported cfMeDIP-seq (plasma cell-free methylated DNA immunoprecipitation sequencing) applied to 55 pleural mesothelioma patients and 24 asbestos-exposed controls. A random forest classifier achieved 91% accuracy, 88% precision, and 90% recall for distinguishing mesothelioma from non-cancer controls; the classifier also discriminated histological subtypes.

The IMPRESS tissue assay (bisulfite-free methylation detection, 744 hypermethylated CpG sites), published in Molecular Oncology in 2026, achieved:

• Sensitivity 89.2% and specificity 93.5% for differentiating tumoral from non-tumoral pleura
• Sensitivity 85.2% and specificity 100% for distinguishing pleural mesothelioma from pleural metastases

A 2025 Nature Medicine Phase 2 study (Johns Hopkins) demonstrated that tumor-informed ctDNA detection can monitor neoadjuvant immunotherapy response in resectable diffuse pleural mesothelioma. Using concurrent tumor and cell-free DNA whole-genome sequencing with machine learning, persistent ctDNA at cycle 3 was associated with shorter PFS (log-rank p=0.0059 pre-surgery), and detectable ctDNA predicted failure to achieve complete surgical resection (Fisher's exact p=0.00013). No liquid biopsy test has received FDA approval specifically for mesothelioma as of May 2026.

How Are Tissue Biomarkers Used to Diagnose Mesothelioma?

WHO 5th Edition Classification (2021) — Key Updates

The WHO Classification of Thoracic Tumours, 5th Edition (2021, IARC Press) introduced critical changes affecting diagnosis:

• Well-differentiated papillary mesothelial tumor (WDPMT) was reclassified as a non-malignant entity (borderline / uncertain malignant potential), distinct from diffuse pleural mesothelioma. WDPMT is associated with TRAF7 and CDC42 mutations (rather than BAP1/CDKN2A alterations), confirming its non-malignant biology — unnecessary chemotherapy should be avoided in confirmed WDPMT cases.
• Mesothelioma in situ was formally recognized as a diagnostic category requiring BAP1 loss and/or CDKN2A deletion for confirmation.
• Localized malignant mesothelioma was retained as a distinct entity, separable from diffuse disease.

Standard IHC Panel: Positive Mesothelial Markers

Per IMIG / WHO consensus, the diagnostic IHC approach uses at least two mesothelial-positive markers AND two epithelial-negative markers, each with >80% sensitivity and specificity, selected based on morphology and clinical context.

Marker	Overall Sensitivity	Epithelioid	Sarcomatoid	Notes
Calretinin	~87.6%	93.2%	16.2%	Nuclear/cytoplasmic; best single marker
WT1	~77%	High	Very low	Nuclear; strong for epithelioid
D2-40 (podoplanin)	~75%	Moderate–high	Lower	Membranous
CK5/6	Variable	~70%	~10%	Less subtype-specific
Mesothelin	~70%	High	Very low	Also expressed in lung adenocarcinoma

Standard Negative (Adenocarcinoma) Markers

• Claudin-4 — highly specific for carcinoma, absent in mesothelioma
• BerEP4 / MOC-31 — positive in adenocarcinoma, negative in mesothelioma
• TTF-1 / Napsin A — lung adenocarcinoma markers, negative in mesothelioma
• CEA — positive in GI-origin adenocarcinoma, negative in mesothelioma

BAP1 IHC — The Key Malignancy Discriminator

Loss of nuclear BAP1 staining by IHC has virtually complete specificity for malignancy in the mesothelial lineage — it is the single most important biomarker for distinguishing malignant from benign mesothelial proliferations:

• Pooled sensitivity: 56% (95% CI 0.50–0.62)
• Pooled specificity: 100% (95% CI 0.95–1.00)

BAP1 IHC can be applied to cytology specimens (effusion cell blocks) with 100% specificity for malignancy, enabling diagnosis of epithelioid mesothelioma from fluid in experienced centers — reducing the need for surgical biopsy in selected cases. Somatic BAP1 mutations or deletions are detected by NGS in approximately 60% of mesothelioma tumors. Germline BAP1 pathogenic variants account for ~1% of sporadic cases overall, but up to 18% in selected testing series; approximately 20% of all pleural mesothelioma may have some form of genetic predisposition.

MTAP IHC as Surrogate for CDKN2A Deletion

MTAP (methylthioadenosine phosphorylase) IHC has been validated as a practical surrogate for CDKN2A homozygous deletion (9p21 locus). Because MTAP is co-located with CDKN2A on chromosome 9p21, homozygous CDKN2A deletion almost invariably results in MTAP protein loss detectable by IHC:

• MTAP IHC loss sensitivity for CDKN2A homozygous deletion: ~95%
• MTAP IHC loss specificity: ~95%

MTAP IHC is simpler, faster, and less expensive than CDKN2A FISH. The combination of BAP1 IHC loss + MTAP IHC loss identifies a large proportion of malignant mesothelial proliferations with 100% specificity — replacing the need for CDKN2A FISH in most centers. FISH is now reserved for cases where IHC results are equivocal.

What Molecular and Genomic Tests Are Used for Mesothelioma?

Targeted NGS Panels (2024–2026)

Clinical-grade NGS panels available for mesothelioma profiling:

Panel	Key Alterations Detected	Mesothelioma Relevance
FoundationOne CDx (Foundation Medicine)	BAP1, NF2, CDKN2A, LATS1/2, TP53, TMB, MSI	FDA-approved CDx; detects actionable alterations
MSK-IMPACT (Memorial Sloan Kettering)	505-gene panel — BAP1, NF2, CDKN2A, SETD2	Research / clinical use at MSK
Tempus xT	648-gene panel including all MPM tumor suppressors	RNA-fusion detection included
Caris Molecular Intelligence	Comprehensive — IHC + NGS + FISH	Multi-platform profiling

The ASCO 2025 Mesothelioma Guideline (Kindler et al.) Recommendation 7.1 (Strong, High evidence quality) recommends offering germline testing to all mesothelioma patients, reflecting recognition that approximately 20% of cases may have a hereditary underpinning.

BAP1 Germline Testing and BAP1-TPDS

Germline BAP1 pathogenic variants cause BAP1 Tumor Predisposition Syndrome (BAP1-TPDS), an autosomal dominant condition conferring up to 85% lifetime risk for at least one BAP1-associated tumor. Associated malignancies include uveal melanoma (most aggressive), pleural and peritoneal mesothelioma, cutaneous melanoma, clear cell renal cell carcinoma, atypical Spitz tumors (MBAITs), and possibly cholangiocarcinoma.

Key clinical differences between germline BAP1-associated and sporadic mesothelioma:

Feature	BAP1-Associated (GR-MPM)	Sporadic (AR-MPM)
Median age at diagnosis	54–56 years	72 years
Male:Female ratio	1:1	5:1
Pleural:Peritoneal ratio	1:1	5:1
Histology	Almost exclusively epithelioid	Mixed
Asbestos exposure	Minimal or none	Strong association
5-year survival	47%	6.7%
Median survival	5–7 years	8–14 months

A 2025 discovery identified a new variant called low-grade BAP1-associated mesothelioma (L-BAM), characterized by a florid phenotype with unique histologic features, found at high prevalence as subclinical disease in BAP1 mutation carriers — biologically distinct and potentially more treatable than conventional pleural mesothelioma. L-BAM is not yet in NCCN / ESMO guidelines.

CDKN2A FISH

CDKN2A homozygous deletion detected by fluorescence in situ hybridization (FISH) has 100% specificity for malignant mesothelial proliferation in cytology and tissue specimens. It is present in approximately 60–80% of sarcomatoid and biphasic pleural mesothelioma but only 15–30% of epithelioid cases. CDKN2A FISH can be applied to cytology specimens (effusion cell blocks), enabling diagnosis from fluid in experienced centers. When combined with BAP1 IHC, the two-test panel achieves near-complete sensitivity across all subtypes.

Is AI Used in Mesothelioma Diagnosis?

Regulatory Status

As of May 2026, no AI-assisted pathology tool has received FDA approval specifically for mesothelioma diagnosis. However, several research-stage tools and broader AI platforms are relevant to mesothelioma diagnostic workflows. Paige PanCancer Detect received FDA Breakthrough Device Designation in April 2025 for AI-assisted cancer detection across multiple tissue and organ types — the first multi-site AI pathology designation. While not mesothelioma-specific, the platform could theoretically flag mesothelioma specimens in mixed pathology workflows.

Published AI Models for Mesothelioma

Model	Type	Task	Performance
MesoNet (Courtiol et al., Nature Medicine 2019)	Deep-learning CNN	Whole-slide outcome prediction without pathologist annotation	Improves overall survival prediction; identifies key histological regions
SpindleMesoNET (Naso et al., Modern Pathology 2021)	CNN	Sarcomatoid mesothelioma vs. benign spindle cell differentiation	AUC 0.989 external validation; accuracy 92.5% (vs. 91.7% expert pathologist average)
SVM biomarker models	Machine learning	Mesothelioma diagnosis from clinical/biomarker data	99.87% accuracy in smaller validation datasets
Multi-model ensembles (DT, SVM, LogR, RF)	Ensemble ML	Mesothelioma diagnosis	Up to 100% accuracy in small validation datasets

FDA-approved AI tools exist for pleural disease detection (e.g., pneumothorax) with sensitivity 84.3–94.6% and specificity 87.9–95.1%, but these are radiology tools — not histopathology tools — and have no mesothelioma-specific validation.

How Is Mesothelioma Distinguished from Other Pleural Diseases?

Key Differential Diagnoses

The principal diagnostic challenge is distinguishing diffuse malignant pleural mesothelioma from:

1. Pleural metastatic adenocarcinoma (lung, breast, GI) — most common mimic; requires negative epithelial IHC markers (Claudin-4, BerEP4, MOC-31, TTF-1)
2. Benign reactive mesothelial proliferation — critical distinction requiring BAP1/MTAP IHC + CDKN2A FISH
3. Fibrous pleurisy — organized inflammatory process; BAP1 / CDKN2A help confirm benign nature
4. Solitary fibrous tumor — STAT6 nuclear positivity and NAB2-STAT6 fusion gene distinguish from mesothelioma
5. Well-differentiated papillary mesothelial tumor (WDPMT) — now classified non-malignant (WHO 5th ed.); TRAF7 / CDC42 mutations distinguish from mesothelioma

The Core Benign-vs-Malignant Workflow

Distinguishing reactive mesothelial hyperplasia from early or focal pleural mesothelioma is the most diagnostically challenging scenario in mesothelioma pathology. The BAP1 IHC + MTAP IHC panel (or BAP1 IHC + CDKN2A FISH) is the current standard:

• If BAP1 loss OR MTAP loss is present → malignant (virtually 100% specificity)
• If neither loss is present → cannot exclude malignancy; repeat biopsy or clinical correlation required

Pleural fluid cytology is essentially non-diagnostic for sarcomatoid mesothelioma — sarcomatoid cells do not exfoliate into pleural fluid. Sensitivity for sarcomatoid mesothelioma from cytology is approximately 6%. Even for epithelioid mesothelioma, cytology sensitivity is only ~35% overall.

Recommended Diagnostic Pathway (IASLC / IMIG / BTS Consensus)

1. Clinical history and CT → suspect pleural malignancy
2. Thoracentesis (fluid cytology + BAP1 IHC + CDKN2A FISH on cell block) — may suffice for epithelioid mesothelioma in expert centers
3. If cytology non-diagnostic or sarcomatoid suspected → CT-guided core needle biopsy (16-gauge; diagnostic yield 93%) or medical thoracoscopy / VATS (gold standard; sensitivity 92–95%)
4. IHC panel on tissue — ≥2 positive mesothelial markers + ≥2 negative epithelial markers
5. BAP1 IHC + MTAP IHC (or CDKN2A FISH) on all specimens to confirm malignancy
6. PET-CT for staging (limited nodal accuracy — upstaging ~30% at surgery)
7. MRI if T3 / T4 chest-wall or diaphragm involvement is suspected
8. Mediastinoscopy or EBUS-EUS if surgical candidate and PET-CT suggests N1 / N2 disease
9. Germline BAP1 testing for all patients (ASCO 2025 Recommendation 7.1, Strong)
10. NGS panel for molecular profiling (prognostic, predictive, trial eligibility)

How Does Histologic Subtype Affect Mesothelioma Diagnosis and Treatment?

The Three WHO Subtypes

• Epithelioid (~55–60%) — polygonal or cuboidal cells with abundant eosinophilic cytoplasm and round nuclei; tubular, trabecular, or solid patterns; best prognosis; most responsive to immunotherapy and chemotherapy; strongest BAP1 IHC positivity
• Sarcomatoid (~10–20%) — spindle cells resembling sarcoma; subvariants include desmoplastic (pure collagen matrix) and transitional; worst prognosis (median OS 4–6 months); unreliable mesothelial IHC marker expression (calretinin positivity only ~16%)
• Biphasic (~20–25%) — contains both epithelioid and sarcomatoid components; intermediate prognosis; requires ≥10% of each component by WHO criteria

Biopsy Concordance with Final Surgical Histology

A landmark 759-patient study established that biopsy technique affects concordance with final surgical histology:

• CT-guided core biopsy — 44% concordance
• VATS-guided biopsy — 74% concordance
• Open surgical biopsy — 83% concordance
• Concordance reached 100% when ≥10 tissue blocks were sampled

A single 1 cm biopsy represents only 0.1% of total tumor burden (~100–1,000 cm³), explaining underestimation of the biphasic component.

Treatment Implications by Subtype (ASCO 2025)

• Non-epithelioid (sarcomatoid / biphasic) — ipilimumab + nivolumab is the preferred first-line regimen (5-year OS 12% vs. 1% with chemotherapy alone; HR 0.48 in CheckMate 743). Chemotherapy alone is not recommended unless immunotherapy is contraindicated.
• Sarcomatoid with ASS1 deficiency (~50% of cases) — may benefit from pegargiminase (ADI-PEG 20) + chemotherapy (ASCO 2025 Conditional Recommendation 4.4).
• Sarcomatoid histology — contraindication for maximal surgical cytoreduction (ASCO 2025 Recommendation 2.3, Strong).

What Is the Peritoneal Cancer Index?

The Peritoneal Cancer Index (PCI) (Sugarbaker system, 0–39 points across 13 abdominal regions) is the standard staging tool for peritoneal mesothelioma. A PCI score ≤20 is generally considered the threshold for cytoreductive surgery (CRS) + HIPEC candidacy; higher scores are associated with incomplete resection and reduced survival benefit. There is no formal TNM staging system specifically validated for peritoneal mesothelioma; the PCI functional score is used clinically as a staging surrogate.

Are There Compensation Implications of Diagnostic Delays?

Mesothelioma's average diagnostic delay of 3–6 months — driven by symptom overlap with benign asbestos-related conditions and the difficulty of distinguishing reactive mesothelial proliferation from early malignancy — has direct legal and financial consequences. Delayed diagnosis can affect asbestos trust fund filing eligibility, statute-of-limitations deadlines for product-liability claims, and a patient's window for treatment trial enrollment. Diagnostic precision matters not only for treatment selection but for legal documentation: histologic subtype, BAP1/CDKN2A status, and exposure history together build the evidentiary record. For specific filing windows, see Mesothelioma_Statute_of_Limitations.

Patients facing a suspected or confirmed mesothelioma diagnosis should pursue both an experienced mesothelioma specialist and a qualified mesothelioma attorney early — diagnostic milestones and compensation deadlines run in parallel, not sequentially.

Frequently Asked Questions

What is the most accurate test to diagnose mesothelioma?

Tissue biopsy with immunohistochemistry remains the gold standard for diagnosing mesothelioma. The most diagnostically powerful combination in 2025–2026 is BAP1 IHC + MTAP IHC (or BAP1 IHC + CDKN2A FISH) — loss of either marker has virtually 100% specificity for malignancy in the mesothelial lineage. VATS-guided biopsy delivers 92–95% sensitivity and is the surgical gold standard; CT-guided core needle biopsy achieves 93% diagnostic yield. Cytology alone is non-diagnostic for sarcomatoid mesothelioma (sensitivity ~6%) and limited for epithelioid (~35%).

Is there a blood test for mesothelioma?

The MESOMARK assay (soluble mesothelin-related peptides, SMRP) is the only FDA-approved serum biomarker, but it is approved for monitoring established mesothelioma — not for primary diagnosis or screening. Pooled sensitivity is approximately 47–68%, with specificity of 86–96%. Emerging liquid biopsy platforms — cfMeDIP-seq methylation profiling (91% accuracy in a 2025 ASCO cohort) and IMPRESS tissue methylation — are investigational and not yet in NCCN, ESMO, or ASCO guidelines as of 2026.

What changed in mesothelioma staging in 2025?

The IASLC TNM 9th edition, published January 2025, replaced the 8th edition's anatomically defined T1–T4 invasion descriptors with pleural thickness sum (Psum) measured at three axial CT levels (apex, hilum, base). The change was driven by superior inter-observer reproducibility and continuous prognostic value. New T-category boundaries: T1 ≤12 mm Psum (median OS 49.8 mo), T2 12–30 mm (27.5 mo), T3 >31 mm (21.1 mo). The N-descriptor was largely retained. The 8th edition stage groupings remain in widespread clinical use during the 2025–2026 transition.

Should everyone with mesothelioma get genetic testing?

Yes. The ASCO 2025 Mesothelioma Guideline (Recommendation 7.1, Strong, High evidence quality) recommends offering germline BAP1 testing to all mesothelioma patients, reflecting the recognition that approximately 20% of cases may have hereditary underpinning. Germline BAP1 carriers (BAP1-TPDS) have markedly better prognosis (5-year survival 47% vs. 6.7%; median survival 5–7 years vs. 8–14 months for sporadic) and qualify their first-degree relatives for cascade screening.

Is AI accurate for diagnosing mesothelioma?

No AI tool has received FDA approval specifically for mesothelioma diagnosis as of May 2026. Research-grade deep-learning models have demonstrated strong performance: SpindleMesoNET (Naso et al., 2021) achieved AUC 0.989 and 92.5% accuracy for distinguishing sarcomatoid mesothelioma from benign spindle-cell proliferation — equal to or exceeding the 91.7% average accuracy of expert pathologists. MesoNet (Courtiol et al., 2019) improves overall survival prediction from whole-slide images without pathologist annotation. Paige PanCancer Detect received FDA Breakthrough Device Designation in April 2025 for multi-site cancer detection but is not yet cleared and is not mesothelioma-specific.

What is the difference between BAP1 IHC and BAP1 germline testing?

BAP1 IHC is a tissue test performed on biopsy or cytology specimens to look for loss of nuclear BAP1 staining in the tumor — a marker of malignancy with ~100% specificity. BAP1 germline testing is a blood-based DNA test looking for inherited pathogenic variants in the BAP1 gene that confer BAP1 Tumor Predisposition Syndrome. The two tests answer different questions: BAP1 IHC asks "is this tissue malignant?"; BAP1 germline testing asks "does this patient have a hereditary cancer-predisposition syndrome?" ASCO 2025 recommends both pathways for appropriate patients.

What is well-differentiated papillary mesothelial tumor (WDPMT)?

WDPMT was reclassified by the WHO 5th Edition Classification of Thoracic Tumours (2021) as a non-malignant entity, distinct from diffuse pleural mesothelioma. WDPMT carries TRAF7 and CDC42 mutations (rather than BAP1 / CDKN2A alterations), which provides molecular confirmation of its non-malignant biology. Distinguishing WDPMT from diffuse malignant mesothelioma is clinically critical — confirmed WDPMT should not receive chemotherapy.

Why does mesothelioma take so long to diagnose?

Diagnostic delay in mesothelioma — typically 3–6 months between symptom onset and confirmed diagnosis — reflects several converging factors. First, presenting symptoms (cough, dyspnea, pleural effusion, weight loss) overlap with common benign asbestos-related conditions and other malignancies. Second, distinguishing early or focal mesothelioma from reactive mesothelial proliferation requires specific IHC (BAP1, MTAP) and FISH (CDKN2A) panels that are not universally available outside expert centers. Third, sarcomatoid mesothelioma is essentially non-diagnostic on pleural fluid cytology (sensitivity ~6%), requiring tissue biopsy. The mean latency from asbestos exposure to mesothelioma diagnosis is 30–50 years, which often makes the exposure history non-obvious at presentation.

Related Pages

• Mesothelioma_Diagnosis — overview of mesothelioma diagnostic process
• Mesothelioma_Biopsy_Procedures — biopsy techniques, diagnostic yield, complications
• Mesothelioma_Staging — TNM staging, Brigham staging, stage-specific prognosis
• Pleural_Mesothelioma — pleural mesothelioma comprehensive overview
• Peritoneal_Mesothelioma — peritoneal mesothelioma diagnosis and treatment
• Treatment_Options — FDA-approved treatments and clinical trials
• Mesothelioma_Specialists — finding expert mesothelioma centers
• Mesothelioma_Statute_of_Limitations — legal filing windows post-diagnosis
• Asbestos_Trust_Funds — compensation pathways for diagnosed patients